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Abstract
Intraventricular hemorrhage is a common cause of morbidity and mortality in premature
infants. The rupture of the germinal zone into the ventricles entails loss of neural stem cells
and disturbs the normal cytoarchitecture of the region, compromising late
neurogliogenesis. Here we demonstrate that neural stem cells can be easily and robustly
isolated from the hemorrhagic cerebrospinal fluid obtained during therapeutic
neuroendoscopic lavage in preterm infants with severe intraventricular hemorrhage. Our
analyses demonstrate that these neural stem cells, although similar to human fetal cell
lines, display distinctive hallmarks related to their regional and developmental origin in the
germinal zone of the ventral forebrain, the ganglionic eminences that give rise to interneu-
rons and oligodendrocytes. These cells can be expanded, cryopreserved, and differenti-
ated in vitro and in vivo in the brain of nude mice and show no sign of tumoral
transformation 6 months after transplantation. This novel class of neural stem cells poses
no ethical concerns, as the fluid is usually discarded, and could be useful for the develop-
ment of an autologous therapy for preterm infants, aiming to restore late neurogliogenesis
and attenuate neurocognitive deficits. Furthermore, these cells represent a valuable tool
for the study of the final stages of human brain development and germinal zone biology.
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1 | INTRODUCTION
Intraventricular hemorrhage (IVH) is a common complication of pre-
mature infants, occurring in 15% to 40% of preterm infants weighing
less than 1500 g at birth and being particularly common in extremely
low birthweight neonates.1-3 IVH is classified into four grades
according to the extent of hemorrhage, development of subsequent
ventricular dilatation, and parenchymal involvement: grade I—a hem-
orrhage restricted to subependymal region; grade II—a hemorrhage
bleeding into de ventricles without dilation; grade III—an IVH with
ventricular dilatation; and grade IV—an IVH with associated adjacent
brain parenchyma infarction.4 Some authors classify grade IV IVH sep-
arately because the presence of periventricular hemorrhagic infarction
or other parenchymal lesions is generally not caused simply by exten-
sion of IVH into brain parenchyma and should thus be considered as a
different pathological condition.5 Around 10% to 15% of preterm
infants develop severe (grade III-IV) IVH and those infants are at high
risk to develop posthemorrhagic hydrocephalus, an expansion of the
ventricles due to cerebrospinal fluid (CSF) accumulation (reviewed in
Reference 6), and to present long-term neurological deficits with cog-
nitive and motor disabilities.6,7 IVH initiates in the periventricular ger-
minal zone (Gz), also known as germinal matrix, a highly proliferative,
highly vascularized region around the lateral ventricles with a dense
and fragile, endothelial-lined, vessel network.8 From 24 to 32 weeks
of gestation the Gz is most prominent in the caudo-thalamic groove,
forming the ganglionic eminences of the ventricular zone (VZ), where
late migrating cortical and thalamic neurons and oligodendrocyte pre-
cursors are born.9 The ultimate cause of Gz bleeding remains unclear,
but it is commonly accepted that it results from the combination of
Gz vasculature vulnerability and blood pressure fluctuations associ-
ated with prematurity.8 In the hemorrhage phase, there is a rupture of
the Gz, occurring most often at the level of the medial ganglionic emi-
nence, that entails loss of neural stem cells (NSCs) and disturbs the
cytoarchitecture of the zone leading to abnormal neuronal,
ependymal, and glio-genesis.10,11 Current treatments for IVH are
intended to decrease the intracranial pressure that can cause per-
iventricular white matter compression and damage, impairment of
brain development, and even death.12,13 There is a standardized pro-
tocol neither for the type nor for the timing of the intervention,14-16
but it has recently been shown that early removal of hemorrhagic CSF
by neuroendoscopic lavage is a safe procedure that may mitigate the
adverse effects of the accumulation of blood products, decrease the
need for permanent shunt placement, and potentially reduce neuro-
logical disability.17-19
NSCs are the self-renewing, multipotent cells that generate neuronal
and glial cell populations during development. During brain development,
primary NSCs located in the VZ have radial processes (apical radial glial
cells), divide symmetrically, are highly polarized, and express prominin-1
(CD133).20 Radial glia are more multipotent than the intermediate progen-
itors of the subventricular zone (SVZ) that include basal radial glia, tran-
sient amplifying, and neural progenitors.21,22 Regional differences in the
transcriptional profile of radial glia dictate the fate of their postmitotic
progeny. In addition to their differentiation potential, NSCs produce neu-
rotrophic and neuroprotective molecules, making them attractive for
regenerative approaches.23,24 In this regard, clinical-grade human NSC
lines are usually obtained from the fetal central nervous system (CNS).
Human NSCs can also be isolated from the adult CNS in patients undergo-
ing surgical procedures,25 or be derived from pluripotent stem cells (PSC)
and from somatic cells through reprogramming protocols.24,26 Advanced
therapy medicinal products based on clinical-grade human allogenic fetal
NSCs are being tested in clinical trials for various neurological disorders
and, although efficacy has yet to be ascertained in a clinical setting, their
safety profile has been repeatedly confirmed (reviewed in Reference 24).
Significance statement
Intraventricular hemorrhage (IVH), occurring in 15% to 40%
of preterm births, is frequently associated with long-term
neurological deficits. The rupture of the proliferative germi-
nal zone in IVH disturbs late neuronal, ependymal, and
glio-genesis. Using a minimally invasive neuroendoscopic
procedure, neural stem cells can be retrieved from the cere-
brospinal fluid, which can be expanded, cryopreserved, and
differentiated in vitro and in vivo, and are not tumorigenic.
These cells display distinct hallmarks related to their origin
in the germinal zone of the ventral forebrain and could be
useful for the development of an autologous cell therapy
aiming to attenuate neurocognitive sequelae.
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Here we demonstrate that a novel class of NSCs can be robustly
isolated from the hemorrhagic CSF of preterm neonates during
neuroendoscopic lavage. These NSCs that we named Gz-NCS display
distinctive features corresponding to their origin in the ventral fore-
brain. Gz-NSCs could be useful to develop an autologous cell therapy
aiming to reduce neurological disability in preterm infants and to fur-
ther our understanding of human Gz biology.
2 | MATERIALS AND METHODS
2.1 | Hemorrhagic CSF collection
CSF samples were obtained from eight preterm infants with grade IV
IVH (Table 1) at the Hospital Universitario Virgen del Rocío (Sevilla,
Spain). The study was approved by the Hospital Universitario Virgen
del Rocío ethical committee and has been performed in accordance
with the 1964 Declaration of Helsinki. All samples were obtained after
parental informed consent. The SSPA Biobank has coordinated the
collection, processing, management, and assignment of the biological
samples used in this study, according to the standard operating proce-
dures established for this purpose. Under intraoperative ultrasound
guidance27 (Video S1) the ventricle with the larger amount of blood
was punctured with the surgical endoscope (MINOPModular
Neuroendoscopy system, Aesculap, Inc., Center Valley, Pennsylvania)
and the content was collected. Briefly, the neurosurgical endoscopy
system has two irrigation channels, a scope channel, and a working
channel, allowing the simultaneous irrigation and collection of liquids
during the surgical procedure. The endoscope is introduced through a
minimal precoronal corticotomy, one channel is connected to an infu-
sion line, and another channel to an outflow line open at the third
ventricle level so that there is no positive resistance to liquid exit,
being the system pressure close to 0 H2O cm; the infusion rate is
determined by gravity (1.8 m) so that there is no risk of inadvertently
causing hypertension during the procedure. Additionally, the neuro-
surgeon constantly monitors the fontanel tension and can open or
close the lines to stabilize the pressures. The CSF is collected in
50 mL syringes connected to the outflow channel to minimize
exerting an excessive suction. Once the initial hypertension is
corrected, continuous irrigation is established using warm, lactated
Ringer solution (Baxter, # FE2303) by passive inflow and outflow
through the second channel (1.4 mm wide), which was also collected
(lavage) in successive syringes until clear. Irrigation was stopped once
the fluid within the ventricular system was clear, or at any time if
hemodynamic instability appeared. Typically, 1000 to 2000 mL of
Ringer solution were used and collected in 50 mL sterile syringes that
were immediately closed to maintain sterility. The bleeding area was
sealed with fibrinogen beads (Floseal, Baxter #ADS201845).
2.2 | NSC isolation from hemorrhagic CSF
CSF samples were transferred to appropriate tubes and centrifuged at
370g for 10 minutes. The cell pellet was resuspended in N2/B27 medium:
Dulbecco's modified Eagle medium (DMEM)-F12 (ThermoFisher Scientific
#11530566), 0.1 mM nonessential amino acids (Sigma-Aldrich
#RNBG4911), 100 IU penicillin/100 μg/mL streptomycin (Sigma-Aldrich
#P0781), 2 μg/mL heparin (Rovi #641647), 1% N2 (ThermoFisher Scien-
tific #11520536), 1X B27 (ThermoFisher Scientific #11530536), 20 ng/
mL FGF (Miltenyi Biotec #130-093-564), 20 ng/mL EGF (Peprotech #AF-
100-15), and 10 ng/mL LIF (Miltenyi Biotec #130-108-156). The cell sus-
pension was seeded onto 20 μg/mL poly-L-ornithine (Sigma-Aldrich #
P4957)/20 μg/mL laminin from human placenta (Sigma-Aldrich #L6274)
(POL) or Matrigel (Corning #354277)-coated plates. Medium was changed
24-48 hours after seeding. Cells were seeded for expansion at 1 × 105
cells/mL in low binding flasks or at 12 000 cells/cm2 in Matrigel- or POL-
coated plates. Matrigel-coated flasks were prepared by incubation with
Matrigel diluted in cold DMEM-F12 for 1 hour at room temperature
according to manufacturer's instructions. For POL coating, flasks were
incubated with 20 μg/mL poly-L-ornithine for 1 hour at 37C or overnight
at 4C. Flasks were washed twice with distilled water and they were then
further incubated with 20 μg/mL laminin for 2 hours at 37C. Flasks were
washed three times with phosphate buffered saline (PBS, ThermoFisher
Scientific #A12856-01) before cell seeding. Cells were expanded for
3 (early) and 7-10 (late) passages for characterization. Passage 7, which
corresponds to 13 ± 1 accumulated population doublings, was considered
“late passage” given that it will not be possible to extensively expand the
cells in a clinical setting.
Magnetic activated separation (MACS) was performed using the
CD133 MicroBead kit (Miltenyi Biotec #130-097-049) following man-
ufacturer's instructions.
2.3 | Immunofluorescence
Cells grown over Matrigel-coated coverslips were fixed with 4% para-
formaldehyde (SantaCruz Biotechnology #SC-281692), permeabilized
with 0.1% Triton X-100 (Sigma-Aldrich #T8787), blocked in PBS
(ThermoFisher Scientific #A12856-01) with 1% bovine serum albumin
(BSA, Sigma-Aldrich #A8806) for 30 minutes at 37C and incubated
with the primary antibody overnight at 4C. Cells were subsequently
TABLE 1 Hemorrhagic cerebrospinal fluid samples
Batch Weight (g) Sex EGA (weeks)
Case 1 2150 Male 33
Case 2 1950 Male 36
Case 3 1600 Male 30
Case 4 1142 Female 27
Case 5a 3120 Female 42
Case 6 1120 Male 29
Case 7 850 Male 29
Case 8 805 Female 28
aCD133 expression dropped drastically with passages and therefore cells
isolated from this sample were excluded from further analysis.
Abbreviation: EGA, estimated gestational age at CSF collection.
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incubated with the secondary antibody for 30 minutes at 37C and
mounted with ProLong Gold Antifade Mountant with 40,6-diamidino-
2-phenylindole (DAPI, ThermoFisher Scientific #P36930). Primary and
secondary antibodies are listed in Table S1. For Ki-67 detection, we
first performed an antigen retrieval step in which cells were heated
for 10 seconds in a microwave with citrate buffer pH 6.0 (Sigma-
Aldrich #C9999) letting cells cool down 20 minutes. Acquisition of
fluorescence images was performed in a Leica TCS-SP5 or a Nikon
Eclipse Ti fluorescence microscope. Images were processed using the
Adobe Photoshop CS5 or ImageJ software.28 Positive cells were
counted using the ImageJ software from at least three random fields
per preparation.
2.4 | Flow cytometry
For CD133, CD24, CD34, CD45, PODXL, IL1RAP, and MHC detec-
tion, live cells were blocked in PBS with 1% BSA and incubated with
conjugated antibodies for 15 minutes at 4C. For TREK2, FZD5, and
DLK1 analysis, cells were fixed with 3.7% formaldehyde (Sigma-
Aldrich #F8775), permeabilized with 0.1% Triton X-100 (Sigma-
Aldrich #T8787), blocked in PBS with 1% BSA and incubated with the
primary antibody for 30 minutes at 4C. Cells were subsequently incu-
bated with the secondary antibody for 30 minutes at 4C. Antibodies
are listed in Table S1. Fluorescence was estimated with a Macs Quant
flow cytometer (Miltenyi Biotec) and results were analyzed with the
MacsQuantify 2.10 and FloJ v10 software. Appropriate isotype con-
trols were run in parallel with the samples. Gating strategies for the
different antibody panels are shown in Figure S1.
2.5 | Transcriptomic analysis
2.5.1 | Control stem cell samples
Human fetal NSCs (n = 4) were derived from the forebrain of 15- to
22-week-old fetuses that had undergone spontaneous in utero death
(miscarriage). Tissue procurement was approved by the Ethics Com-
mittee of the Institute “Casa Sollievo della Sofferenza” after receiving
the mother's informed, written consent. These fetal NSC lines have
been extensively characterized.29-31
PSC-derived NSCs (iPS-NSC, n = 6) were differentiated from
embryoid bodies (EBs) in TeSR2 medium (Stemcell Technologies
#05860) spiked with Rock inhibitor (Y-7632; 10 μM; Tocris Biosci-
ence #1254). After 7 days, EBs were plated on Matrigel and cul-
tured in neural differentiation media. On day 10, 0.1 μM retinoic
acid (RA, Sigma-Aldrich #R 2625) was added to the medium. On
day 15, neural tube-like rosettes were mechanically detached and
F IGURE 1 Neuroendoscopy and CSF collection. A, Schematic representation of the germinal zone localization (in blue) around the ventricles
(axial view) that comprises the ventricular and subventricular zones where neural stem cells are found (box). B, Computed tomography axial brain
images depicting the bleeding area close to the head of the caudate nucleus and the presence of blood inside the ventricular system (arrows) in
one of the cases. C, Recovery of hemorrhagic CSF and irrigation fluid from preterm infants with IVH grade IV. Images of the surgical intervention
by neuroendoscopy: preparation (i); neuroendoscopic imaging of bleeding area before (ii) and after (iii) irrigation, and, before (iv) and after
(v) sealing; collection of irrigation fluid (vi)
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cultured in neural differentiation media with 20 ng/mL FGF
(Miltenyi Biotec #130-093-564) and 20 ng/mL EGF (Peprotech
#AF-100-15). Cells were expanded in suspension as neurospheres
or in adhesion over Matrigel during 6 to 7 passages before RNA
extraction for transcriptomic analysis.
Three human PSC lines were included for reference. CBiPS were
derived from CD133+ umbilical cord cells. These cells are available
from the Spanish national repository, (BNLC) and the data regarding
cell characterization can be downloaded at http://www.eng.isciii.es.
WA09 (H9) were purchased fromWiCell and the characterization data
can be downloaded at www.wicell.org. L6-iPS was generated by our
group (see experimental procedures in Supplementary Information)
and we are in the process of banking it at the Spanish BNLC. Charac-
terization of this cell line is provided in Figure S2.
Umbilical cord blood samples (CD34+ HSC, n = 3) were
obtained from the Banc de Sang i Teixits, Barcelona. CD34+ cell
purification was performed as previously described.32 Briefly,
mononuclear cells (MNC) were isolated from CB using
Lympholyte-H (Cederlane #CL5015) density gradient centrifuga-
tion. CD34+ cells were positively selected using Mini-Macs immu-
nomagnetic separation system (Miltenyi Biotec #130-046-702,).
Purification efficiency was determined by flow cytometry analysis
staining with CD34-phycoerythrin (PE; Miltenyi Biotec
#130-120-520) antibody.
2.5.2 | Expression microarrays
RNA was extracted with RNeasy Mini kit (Qiagen #74104) following the
instructions of the manufacturer and sent to the Genomics Unit of the
Andalusian Center of Molecular Biology and Regenerative Medicine
(CABIMER). RNA quality was analyzed by the Bioanalyzer 2100 (Agilent).
All samples had RNA Integrity Number (RIN) higher than 9. cDNA was
synthetized, labeled with biotin and hybridized with independent Human
Clariom-S Microarrays, (Affymetrix #902927) following Affymetrix proto-
col. Microarrays were scanned with Affymetrix GeneChip Scanner 3000
7G, and the obtained data were analyzed with the Affymetrix GeneChip
Command Console 2.0 software. The microarray expression data set is
publicly available at the GEO repository under the identifier GSE124361.
Further analyses were performed using the Transcriptome Analysis Con-
sole (TAC, Affymetrix) v4.0 software and R version 3.5.0.33 Functional
enrichment analysis was performed using the bioinformatics tool EnrichR
(http://amp.pharm.mssm.edu/Enrichr/).34,35 Neuroanatomical references
were obtained from the Allen Atlas of the developing human brain
(www.brainspan.org).36
2.5.3 | RT-PCR
First, 0.1 μg of RNA were used for cDNA synthesis using Oligo-dT
(Invitrogen #18418012), RNase OUT (Invitrogen #10777-014) and
SuperScriptII Retrotranscriptase (Invitrogen #18064-014). PCR
products were obtained using 5 ng of cDNA and Mytaq Red DNA
Polymerase (Bioline #BIO-21108) following the manufacturer's
instructions. Oligonucleotides used for amplification are provided
in Table S2.
2.6 | Transplantation into nude mice
Animal care and experimental procedures were conducted
according to the current National and International Animal Ethics
Guidelines and approved by the Italian Ministry of Health. Ten
7- to 8-week-old female athymic Nude-Foxn1nu mice (#6902F,
Envigo) received a single injection of 300 000 CD133+ cells in the
striatum. Stereotaxic coordinates were determined using the
Paxinos and Franklin atlas37 and the injections were done at:
anteroposterior, 0 mm; dorsolateral, 2.5 mm from bregma; and dor-
soventral, −2.7 mm from dura matter. All the injections were per-
formed on the right hemisphere. Cells were injected in 3 μL during
5 minutes using HBSS (Gibco #14175095) as vehicle. Three animals
were sacrificed at 3 weeks to assess survival and proliferation and
seven animals were sacrificed at 6 months. Transplantation experi-
ments and analyses were performed as previously described for
fetal NSCs.29,38 For immunohistochemical analysis, brains were
perfused-fixed with ice-cold 4% paraformaldehyde (Sigma
#158127), postfixed overnight, cryoprotected and sectioned in a
cryostat. Twenty micrometers coronal sections were serially col-
lected and processed for immunofluorescence.
Quantification of transplanted cells was done using Image J cell
counter-plugin on images acquired in a Nikon C2 confocal microscope
and the NIS Elements 1.49 software. All cells expressing human nuclear
antigen (huN) were counted in sections spanning the graft area, and the
total number was calculated using Abercrombie correction39 and
expressed as the percentage over injected cells. Migration was estimated
as the distance between the first and last sections containing huN
F IGURE 2 Isolation of NSC-like cells from the CSF of IVH patients. A, Phase-contrast microphotographs of CSF-derived NSC cultures at
different days in vitro (DIV) after isolation. Scale bar: 100 μm. B, Exponential growth kinetics of 3 representative NSC lines grown on Matrigel.
C, Phase-contrast microphotographs of cells at early (0) and late (10) passages grown on matrigel. D, Proliferation was assessed by quantification
of Ki-67 expression at early (3) and late (7) passages. A representative confocal section is shown. Scale bar 25 μm. E, Flow cytometry analysis of
CD133, CD24, CD34 and CD45 at early (3) and late (7) passages. There were no significant differences between conditions. Data are shown as
mean ± SEM of 5-7 independent biological samples. The 42-week-old case (pink symbols) was excluded from further analysis. F, Co-expression of
CD133 with CD24 and CD34 at early and late passages. G, Representative microphotographs of the NSC-like cells obtained from the CSF and
the lavage fluid at 13 days after isolation. Scale bar: 100 μm. H, CD133 analysis by flow cytometry of the NSC-like cells obtained from the CSF
and the lavage fluid at passage 3. *P < .05
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positive cells. Coexpression of Ki67, glial fibrillary acidic protein (GFAP),
and OLIG2 was counted in three serial sections of the transplanted ani-
mals (n = 3-7) and expressed as percentage over total huN+ cells in those
sections.
2.7 | Statistics
Data are presented as mean ± SEM. Significance was determined
using two-tailed Student's t test for comparisons between two
samples. P < .05 was considered significant. Paired t-tests or
repeated measures (R) ANOVA were used to compare samples from
the same individual at different stages. All statistical analyses were
performed using the GraphPad Prism 8.01 software. Bioinformatic
analyses were performed using the Affymetrix and R software,
using t, ANOVA, and R-ANOVA tests and selected thresholds, as
indicated in the text and figure legends. A false discovery rate
(FDR) <5% was established for significance.
3 | RESULTS
3.1 | Hemorrhagic CSF of preterm IVH patients
contains NSCs
Eight consecutive cases with a clinical and radiological diagnosis of
grade IV IVH (Table 1) underwent a ventricular neuroendoscopy to
seal the bleeding area and remove the hemorrhagic CSF from the ven-
tricular cavities (Figure 1, Video S1). Neuroendoscopic lavage was per-
formed following the technique reported by Schulz et al18 with a few
modifications as detailed in the Methods section. The content of the
first syringe (collected before starting the irrigation) was processed for
cell recovery. After centrifugation, the cell pellet was initially seeded
on POL or Matrigel-coated plates and cultured in an N2/B27 serum-
free medium with mitogens; 24-48 hours after seeding, small aggre-
gates were observed amidst abundant erythrocytes and blood cells in
suspension (Figure 2A). Cells were enzymatically dissociated and pas-
saged as neurospheres or in adhesion for 10 passages showing a dou-
bling time of 3.94 ± 0.33 days and maintaining a stable growth curve
and morphology (Figure 2B,C). Quantification of Ki-67 showed no sig-
nificant decrease in proliferation between early and late passages
(12.77 ± 8.88 vs 18.83 ± 7.44; Figure 2D). Likewise, expression of the
stem cell marker prominin-1 (CD133) was maintained through pas-
sages (58.99 ± 8.7 vs 57.93 ± 10.82; Figure 2E). An exception was the
42-weeks-old sample (Figure 2E, pink symbols) in which the percent-
age of CD133+ cells dropped drastically upon passaging. This case
was excluded from further analyses given that IVH in full-term neo-
nates most often originates in the choroid plexus.8
We next analyzed whether the cell population obtained from
hemorrhagic CSF had a similar expression pattern of CD surface anti-
gens than that described for fetal NSCs.40,41 Like fetal NSCs, most
cells in CSF samples were positive for CD133 and all were negative
for CD45, displaying a variable expression of CD24 (Figure 2E and
Table S3). Intriguingly, some samples contained a substantial percent-
age of CD34 positive cells (Figure 2E and Table S3), which is not
expressed by fetal forebrain NSCs.40 On average, 18.10 ± 7.65% of
the cells were CD133+CD34+ at passage 7, and 49.42 ± 10.65 of the
cells were CD133+CD24+ at passage 7. Despite no significant differ-
ences, there was a trend to an increase of CD24 double positive cells
with passages (29.13 ± 7.4 vs 49.42 ± 10.65; Figure 2F and Table S3).
We attempted to recover cells from subsequent CSF samples, col-
lected once the irrigation started, but the flow cytometry analyses
showed fewer CD133+ cells in the lavage fluid (66.26 ± 12.47 vs
26.18 ± 15.83; P = .02 [paired t test]; Figure 2G,H) so the rest of the
study was carried out using only the first tube of hemorrhagic CSF
from each case.
In another experiment, we failed to recover NSC-like cells from
nonhemorrhagic CSF samples (see supplementary experimental proce-
dures and Figure S3) obtained from a different set of patients with
obstructive hydrocephalus, although in some cases, changing to a
serum-based media allowed us to grow fibroblast-like, adherent cells
from samples with large CSF volumes (>20 mL).
3.2 | NSCs isolated from the hemorrhagic
cerebrospinal fluid present distinctive regional
hallmarks
We next performed a transcriptomic analysis to study the differences
and similarities between NSCs isolated from hemorrhagic CSF, fetal
forebrain NSCs and NSCs derived from iPSCs. Given that CSF samples
contained mostly blood cells we also included in the analysis
F IGURE 3 NSC cells isolated from the CSF display a ventral forebrain gene-expression profile. A, PCA analysis of global gene-expression
profiles. B, Venn diagrams showing the number of differentially expressed genes (DEG), 2-fold change, FDR P < .05. C, Volcano plot of DEG in
NSCs from fetal brain (red) and CSF (blue) sources. Highlighted are markers that identify regional populations including genes that have been
previously associated with germinal zones and forebrain regionalization (see also schematic in D) and putative candidates for prospective
identification of germinal zone NSCs. Expression levels of NSC and regional forebrain markers (D) and candidate DEG genes that could identify
this NSC population (E). F, Semi-quantitative RT-PCR of NSC markers and candidate DEG genes. G, Enrichment network analysis of upregulated
genes relative to fetal NSCs, profiled across brain regions according to the Allen brain atlas, and schematic neuroanatomical representation on
coronal brain sections showing their periventricular location. A, anterior; BNST, bed nuclei of the stria terminalis; cGE, caudal ganglionic
eminence; Cd, caudate nucleus; D, dorsal; DThal, dorsal thalamus; GP, globus pallidus; lGE, lateral ganglionic eminence; mGE, medial ganglionic
eminence; P, posterior; Put, putamen; Sept, septum; SVZ, subventricular zone; Thal, thalamus; V, ventral; V Pall, ventral pallidum; VZ,
ventricular zone
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hematopoietic stem cells (CD34+ CB-HSC) and the iPSC used to obtain
iPS-NSCs. Principal component analysis (PCA) mapping and hierarchical
clustering of global gene-expression profiles showed that NSCs from
CSF clustered together with fetal NSCs, being farther away from iPS-
derived NSCs (Figure 3A). Pairwise comparisons showed a significant
overlap in the expression profiles of the three types of NSCs (Figure 3B).
Notwithstanding, there were 1073 differentially expressed genes (DEG)
between CSF-derived NSCs and fetal NSCs, using a false discovery rate
(FDR) P value < .05 and ±2-fold change (Figure 3C). Consistent with an
NSC identity, expression of radial glia and neural progenitor markers,
such as SOX2, FABP7, FOXG1, and NES was similar in CSF-derived and
fetal NSCs (Figure 3D). GFAP was highly expressed in both types, but
significantly higher in the NSCs from CSF. GFAP expression is restricted
to the VZ during primate brain development.36,42 Likewise, other tran-
scripts enriched in human VZ relative to the SVZ, (the secondary prolifer-
ative area) such as SPP1, DLK1, IL1RAP,43 or ID3, a marker of quiescent
NSCs, were also higher in CSF than in fetal NSCs. On the other hand,
expression of EGFR—which marks NSC activation—or regulators of line-
age commitment, such as AQP4, SP8, or ZIC3, as well as more mature
neuronal markers like SOX1 or MAPT was higher in fetal forebrain NSCs
(Figure 3C). There were also remarkable differences in the expression of
forebrain regional transcription factors (Figure 3D) with high expression
of ventral and posterior forebrain markers, OTX2 and NKX2.1, while dor-
sal ones such as PAX6 and GSX2 were lower than in fetal NSCs. In addi-
tion, we identified several markers that could provide a distinctive
signature for this NSC population (Figure 3C,E). Among those, there was
a remarkable upregulation of genes related to antigen presentation and
immune response, in particular pertaining to the major histocompatibility
complex II (MHCII) (Figure 3E), which according to the developmental
human brain atlas are highly expressed in germinal zones during mid-
gestational stages (www.brainspan.org).36 Differential expression of
selected transcripts was validated by PCR (Figure 3F) Interestingly,
enrichment analysis showed that the genes upregulated in CSF-derived
NSCs relative to fetal NSCs mapped to the ventral forebrain structures,
including the periventricular nuclei—basal ganglia, thalamic, and septal
nuclei (Figure 3G). This regional topography corresponds to the anatomi-
cal structures surrounding the ganglionic eminences, most often affected
by IVH in preterm infants. This is consistent with an origin of the cells
isolated from the CSF in the germinal zone of the ventral forebrain and
therefore we have named them Gz-NSCs.
Next, we used immunofluorescence to evaluate the expression at
the protein level of typical radial glia markers such as SOX2, nestin,
and brain lipid binding protein (BLBP, FABP7). Quantification con-
firmed expression of these proteins by most cells (SOX2:
96.57 ± 1.56; NESTIN: 84.40 ± 4.27; BLBP: 80.80 ± 10.83;
Figure 4A). In addition, the majority of the cells expressed regional
transcription factors corresponding to ventral and posterior forebrain,
NKX2.1 and OTX2, and not the dorsal forebrain marker PAX6
(NKX2.1:82.46 ± 4.73; OTX2: 82.33 ± 2.88; PAX6: 0.97 ± 0.48;
Figure 4B). Other differentially expressed transcripts that we selected
based on a putative membrane localization were also expressed at the
protein level (Figure 4C). However, one of these, PLPP4, a poorly
characterized phospholipid phosphatase expressed in the brain (www.
proteinatlas.org)44 showed a clear nucleolar localization pattern.
To establish the differentiation potential of Gz-NSCs, we cultured
the cells in FBS without mitogens for 2 weeks. Cells showed in vitro tri-
lineage potential, upregulating neuronal, astrocyte, and oligodendrocyte
markers in various proportions as shown in the graph (Figure 4D), and
downregulating Ki67 (P < .01 compared with undifferentiated cells).
Because OLIG2 is also expressed in neuronal progenitors, we examined
the coexpression of OLIG2 and doublecortin (DCX). About 10% (9.9 ± 7)
of the OLIG2 positive cells coexpressed DCX in these in vitro conditions,
representing 1.5% of the total cells (Figure 4E). To further confirm differ-
entiation into glial lineages, we also examined the expression of PDGFR,
another oligodendrocyte marker, and S100β that was consistently
coexpressed with GFAP in Gz-NSCs differentiated in 2% B27 for
2 weeks (Figure S4).
3.3 | CD133+ purified cells maintain Gz-NSC
features
Cells initially isolated from hemorrhagic CSF samples are a hetero-
geneous mixture of cellular types at different developmental and
maturation stages, in particular taking into account that all these
cases had parenchymal involvement (grade IV). Therefore, in order
to better define putative Gz-NSC-specific features and obtain a
more homogenous population for future in vivo applications, we
selected CD133+ cells by magnetic activated cell sorting (MACS).
CD133 has been used for the isolation of NSCs from normal brain
tissues and CD133+ cells differentiate in vitro and in vivo into the
three neuroectodermal lineages.40,45-47 Following MACS purifica-
tion, we could expand and cryopreserve the cells, which maintained
their typical morphology and the expression of CD133 (Figure 5A).
The percentages of CD34+ and CD24+ double positive cells were
variable and did not significantly change with sorting, although we
observed that CD34+ cells tended to remain in the negative frac-
tion (Figure 5B).
F IGURE 4 The cells isolated from hemorrhagic CSF display NSC features. Expression of NSC markers SOX2, Nestin, and BLBP (FABP7)
(A) and regional markers NKX2.1, OTX2 and PAX6 (B) by immunofluorescence and corresponding quantification of at least 3 independent
biological replicates. Scale bar: 25 μm. C, Immunofluorescence analysis of the expression of PLPP4, FZD5, TREK2, PODXL, MHC II, DLK1,
PARM1, and IL1RAP in Gz-NSCs. Representative confocal images of at least 3 independent biological replicates. Scale bar: 50 μm. D, Neural tri-
lineage differentiation into β-III-tubulin (βIIItub), glial fibrillary acidic protein (GFAP) and OLIG2 positive cells. Downregulation of Ki67 was
detected upon differentiation. Representative confocal images (maximum projection) of 3 independent biological samples and corresponding
quantification, shown as percentage over total cells. Scale bar: 50 μm. E, Confocal images and orthogonal z-stack reconstruction showing
colocalization of OLIG2 and doublecortin (DCX) (arrows) in a small percentage of the cells, represented in yellow in the bars. Scale bar: 50 μm
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F IGURE 5 Legend on next page.
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We examined transcriptomic changes related to in vitro propaga-
tion and CD133 purification comparing early, late, and CD133+-sorted
Gz-NSCs (R-ANOVA, FDR F < 0.05) with no significant DEG between
early and late passages (Figure 5C). Nevertheless, although there were
no DEG at FDR < 0.05 between early and late passages, they
appeared to be segregated along PCA2 (y-axis, Figure 5C), therefore
we further analyzed the data using a less stringent cutoff (Figure S5).
Those analyses showed that, upon passaging, markers corresponding
to more mature phenotypes tended to decrease, without weakening
the NSC ventral identity (Figure S5).
Upon purification, there were significant changes relative to both
early and late passage cells. Enrichment analysis of the common genes
(early and late vs CD133+) showed that the expression of genes impli-
cated in neural and synaptic specific pathways was decreased
(Figure 5D). On the other hand, CD133+-sorted cells showed a relative
enrichment in genes expressed at less differentiated stages and in less
specific pathways (Figure 5D). Transcriptomic analysis confirmed that
CD133+ cells maintained the expression of radial glia and NSC markers
as well as the pattern of regional transcription factors. Most of the puta-
tive membrane markers that we had selected, including genes related to
antigen presentation, were also expressed (Figure 5E). In contrast,
PARM1 expression was significantly decreased and no longer different
from fetal NSCs. This gene is expressed in a subtype of GABA-vasoactive
intestinal peptide (VIP) interneurons derived from the medial ganglionic
eminence, suggesting that more differentiated cells are lost. KCNK10
(TREK2) expression was significantly decreased, but was still significantly
higher than in fetal NSCs.
We validated the expression of our candidate genes at the pro-
tein level using flow cytometry, before and after MACS enrichment
(Figure 5F). The selected markers were expressed at the protein level
by the majority of the cells (>90.7 ± 9%) and the expression was in
general maintained or increased after CD133 purification with rare
exceptions. MHCII was more variable, although in this case we cannot
discard internalization. In contrast, TREK2 expression was maintained
in most cells (97.5%-95.8%) despite the decrease at the RNA level.
3.4 | Transplantation study
To evaluate the safety of Gz-NSCs, we first verified their trophic
factor dependence (Figure S6A). Cells were expanded until passage
12—which corresponds to 22.25 ± 4.54 accumulated population
doublings—and maintenance of normal karyotype was verified for the
cell lines at this stage (Figure S6B). Recovery of purified and
unpurified cells upon thawing and other cell growth characteristics
relevant to scale-up manufacturing were also analyzed and are shown
in Figure S6.
Next, we transplantedCD133+ purified cells in the striatum of
nude mice (Figure 6A). None of the transplanted animals presented
weight loss, neurological focal signs, or any adverse reactions for
the duration of the study. Using a human-specific antibody (huN),
Gz-NSCs were identified in the striatum of all animals at 3 weeks
(n = 3) and 6 months (n = 7) after transplantation, albeit at low num-
bers (Figure 6B). Transplanted cells formed small grafts that did not
cause anatomical distortion and a few migrated over the striatum
and adjacent white matter tracts, occasionally reaching the VZ
(Figure 6C). Transplanted cells showed low mitotic activity mea-
sured by Ki67 expression (4.59 ± 0.76 and 5.97 ± 2.22; Figure 6D).
Phenotypic analyses showed the presence of human cells
coexpressing GFAP, βIIItubulin or OLIG2 with huN (Figure 6D). At
both time points, the cells appeared to predominantly adopt an
oligodendrocyte fate.
4 | DISCUSSION
We report here the isolation of a distinct class of NSCs, the Gz-NSCs,
from hemorrhagic CSF samples of premature neonates diagnosed
with IVH grade IV. It is well established that NSCs from a given ana-
tomical location give rise to corresponding regional cellular subtypes
and, thus, display transcriptional and phenotypical differences with
NSCs from other locations.48-50 We describe here features of
Gz-NSCs related to their regional and developmental origin in the
ventral ganglionic eminences of the forebrain, which set them apart
from other available human fetal forebrain NSC lines. Importantly,
human interneuron neurogenesis continues into the third trimester of
gestation, largely at the medial ganglionic eminence, which is also a
source of oligodendrocyte precursors. Previous studies have shown
that late neurogenesis is suppressed in premature births and that
IVH arrests proliferation in the Gz at the level of the ganglionic
eminences,9,11 which could result in decreased GABA interneuron
production and decreased myelination due to loss of oligodendrocyte
precursors. These perturbations may contribute to persistent impair-
ments in neurocognitive function in these children.
F IGURE 5 Gz-NSC signature is maintained after CD133 sorting. A, Cell morphology and flow cytometry of CD133 after MACS purification.
Results are the mean of 6 independent biological replicates. Scale bar: 100 μm. B, Flow cytometry analysis of CD24 and CD34 before and after
purification for CD133. Percentages of CD24+ and CD34+ before sorting (blue) and in both the CD133 negative (white) and CD133 positive
(green) fractions showed no significant differences. Data are shown as mean ± SEM of 6 independent biological samples. C, PCA analysis of early,
late, and sorted Gz-NSC populations. D, Venn diagrams representing the transcriptional changes related to cell propagation (early vs late) and
CD133 sorting (2-fold change, R-ANOVA FDR F < 0.05). There were no DEG between early and late passages. Genes downregulated in the
CD133 sorted cells with respect to early and late passages corresponded to GO pathways related to neuronal and synaptic activity while those
upregulated in the sorted cells were indicative of a less differentiated stage. E, Expression of NSCs, regional and Gz-NSC markers at the RNA
level in early, late, and CD133+ purified cells. F, Flow cytometry analysis of PODXL, IL1RAP, MHC II, TREK2, FZD5, and DLK1 expression before
and after MACS purification. Data are shown as mean ± SEM of 6 independent biological samples
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F IGURE 6 CD133+ purified
Gz-NSCs engraft into nude mice.
A, Schematic representation of
CD133+ purified Gz-NSCs
transplantation into the striatum of
nude mice. B, Quantification of huN
positive cells represented as the
percentage over total transplanted
cells. C, Migration of transplanted
cells and a representative image
showing engraftment of Gz-NSCs at
the striatum and subventricular zone
(arrows). An orthogonal
reconstruction shows a HuN
positive cell in the SVZ. D,
Immunofluorescence analysis of the
expression of HuN (green) to
identify human grafted cells and
Ki-67, β-III-tubulin, GFAP, and
OLIG2 (in red). DAPI was used to




quantification of the percentage of
positive cells for each marker.
V, ventricle
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In addition to conspicuous differences in the expression of
regional transcription factors, we report the expression of novel
Gz-NSC markers that differentiate these cells from fetal (dorsal) fore-
brain NSCs and were maintained after sorting for CD133+ cells, such
as PODXL, IL1RAP, HLA-DR, DLK1, and FZD5. These markers could
serve to isolate and identify human Gz-NSCs. However, more cases
are required to validate these given that they can be developmentally
regulated and our samples show some heterogeneity. PODXL is an
interesting glycoprotein involved in apical polarity, which belongs to
the CD34 family of syalomucins, whose absence has been reported to
cause ventricular enlargement in mice.51 PODXL was expressed by
nearly all cells in all samples and expression was maintained after
CD133 sorting in all but one. The interleukin 1 receptor accessory
protein (IL1RAP) is differentially expressed in the human VZ.43 We
confirmed IL1RAP expression in Gz-NSCs at the protein level by flow
cytometry before and after MACS purification. Gz-NSCs showed a
variable expression of MHC class II proteins, which are developmen-
tally expressed in proliferative brain areas (VZ and SVZ) at the level of
the basal ganglia at mid-gestational age (www.brainspan.org).36 Using
IH, the existence of a population of MHC II/SOX2-positive cells in the
Gz of the human embryo, under no proinflammatory conditions, has
been recently reported.52 According to that study, MHC II positive
cells were present in different proportions at all developmental stages
examined, coexpressed SOX2 and, like ours, did not express any
microglial markers (data not shown). The biological relevance of MHC
II expression in nonprofessional antigen presenting cells is not well
understood but it has been suggested that may help modulate local
immune responses and contribute to immunotolerance (reviewed in
Reference 53). Nevertheless, we cannot rule out that, in addition to
intrinsic developmental regulation, which has been demonstrated,
albeit at slightly earlier stages (www.brainspan.org),36 increased levels
of pro-inflammatory cytokines like IFN-γ and IL-4 during the hemor-
rhage stage may induce and upregulate the transactivator CIITA and
the MHC II pathway.54 Further studies are needed to explore this pos-
sibility, as it could have implications for future applications. Indeed,
we cannot rule out that this contributed to the low in vivo survival in
nude mice in our experiment compared with published rates of 40%
for iPS-NSCs or 20% for fetal NSCs.38
Gz-NSCs showed a strong signal at the cell surface for FZD5, the
putative receptor for Wnt5A, which is involved in neural specification
and highly expressed in the VZ55 that was maintained in CD133+
Gz-NSCs. Expression of the noncanonical Notch ligand DLK1, was
also maintained in the sorted population. DLK1 is developmentally
expressed in NSCs in the GEs and maybe involved in the regulation of
the stem cell pool.56 On the other hand, TREK2 (KCNK10) a potassium
channel that has been reported to be expressed by the ependymal
cells57 and upregulated together with GFAP under ischemic condi-
tions in astrocytes58 was transcriptionally downregulated in sorted
Gz-NSCs, yet the protein was maintained. Collectively these data pro-
vide a distinctive Gz-NSC signature that is not dependent on the con-
tribution of more differentiated cell types or contaminating lineages in
the starting samples.
There was a large variability in both CD24 and CD34 positive
populations between samples but it will be necessary to increase
the sample size in order to examine a possible correlation with
developmental stage (age), weight, severity or any other individual
parameter. While CD24 expression has been described in NSCs,
the presence of CD34+ cells was intriguing. We included HSC in
the transcriptomic analysis to rule out a hematological origin of the
CD133 population. In our data set, CD31 (PECAM1), CD53, CD37,
as well as typical leukocyte markers, such as selectin-L or
myeloperoxidase, and erythrocyte markers like fetal hemoglobin
(data not shown), were not expressed by Gz-NSCs, suggesting that
hematopoietic and endothelial stem cells were not present in this
population. Indeed, although it is usually considered a marker of
hematopoietic and endothelial progenitor cells,59,60 CD34 is also
expressed in other lineages, such as the ependymal cells.61 Because
ependymal cells are born in this region at a later developmental
stage and ependymal loss causes a dysregulation of CSF homeosta-
sis contributing to posthemorrhagic hydrocephalus, it will be inter-
esting to study whether the expression of CD34 correlates with
the capacity to generate this phenotype in vivo. In fact, after
sorting we observed that CD34+ cells tended to remain in the nega-
tive fraction, suggesting that they may represent a more mature
phenotype, perhaps in the ependymal lineage.
The shedding of neural progenitors and/or NSCs into the CSF of
IVH and PHH patients had been previously suggested.10,62 Our data
partly support those studies, although, unlike Kruegger et al, we were
not able to isolate NSCs from nonhemorrhagic CSF samples and it is
likely that cells obtained by these authors from indwelling ventricular
catheters represent a different population. Currently, stem cell thera-
pies based on allogeneic umbilical cord-derived cells are being tested
in preclinical and clinical trials.63-67 These cells help to attenuate the
effects associated to inflammation but, so far, no capability to replace
lost tissue has been demonstrated. Although more studies are
required, neuroendoscopic removal of the ventricular CSF in the hem-
orrhagic stage could be indicated in the future not only to ameliorate
the problems associated with the accumulation of blood products and
increased pressure, but also to isolate and bank Gz-NSCs for the pro-
duction of an autologous personalized cell-therapy product directed
to restore late neurogenesis and diminish long-term neurological defi-
cits. In this regard, we performed preliminary safety studies in which
transplantation of Gz-NSC purified CD133+ cells into the striatum of
nude mice resulted in small neural grafts with no tumor formation or
adverse reaction. Moreover, although survival in nude mice was very
limited, a significant proportion of the grafted cells at 6 months
expressed OLIG2, suggesting that Gz-NSC treatment in an autologous
setting could be a safe approach to restore oligodendrogenesis. Col-
lectively our data demonstrate that Gz-NSCs are a distinct population,
which can be expanded, purified, and cryopreserved maintaining their
ventral identity and a favorable safety profile. Therefore, we believe
that Gz-NSCs could be an optimal source to develop a cell therapy for
preterm infants with IVH, for whom other cell therapies are already
being tested.68
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5 | CONCLUSION
Here we describe a novel class of NSCs, the Gz-NSCs that can be eas-
ily and robustly isolated from the CSF of preterm neonates with grade
IV IVH undergoing neuroendoscopic lavage. We found that these
cells, while being similar to fetal forebrain NSCs, have several distinc-
tive hallmarks related to their regional and developmental origin in the
ventral forebrain. Gz-NSCs can be expanded and cryopreserved
showing in vitro and in vivo differentiation potential, and pose no eth-
ical concerns as the fluid is usually discarded. Thus, Gz-NSCs could
represent an optimal source for the development of an autologous cell
therapy for infants with IVH, as well as a useful tool for studying the
late stages of human neural development.
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